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A B S T R A C T   
Numerous combinations of diets and pharmacological agents, including lifestyle changes, have been launched to 
treat obesity. There are still ambiguities regarding the efficacies of different approaches despite many clinical 
trials and the use of animal models to study physiological mechanisms in weight management and obesity 
comorbidities, Here, we present an update on promising diets and pharmacological aids. Literature published 
after the year 2005 was searched in PubMed, Medline and Google scholar. Among recommended diets are low-fat 
(LF) and low-carbohydrate (LC) diets, in addition to the Mediterranean diet and the intermittent fasting 
approach, all of which presumably being optimized by adequate contents of dietary fibers. A basic point for 
weight loss is to adopt a diet that creates a permanently negative and acceptable energy balance, and prolonged 
dietary adherence is a crucial factor. As for pharmacological aids, obese patients with type 2 diabetes or insulin 
resistance seem to benefit from LC diet combined with a GLP-1 agonist, e.g. semaglutide, which may improve 
glycemic control, stimulate satiety, and suppress appetite. The lipase inhibitor orlistat is still used to maintain a 
low-fat approach, which may be favorable e.g. in hypercholesterolemia. The bupropion-naltrexone-combination 
appears promising for interruption of the vicious cycle of addictive over-eating. Successful weight loss seems to 
improve almost all biomarkers of obesity comorbidities. Until more support for specific strategies is available, 
clinicians should recommend an adapted lifestyle, and when necessary, a drug combination tailored to individual 
needs and comorbidities. Different diets may change hormonal secretion, gut-brain signaling, and influence 
hunger, satiety and energy expenditure. Further research is needed to clarify mechanisms and how such 
knowledge can be used in weight management.   
1. Introduction 
Obesity is a global, multifactorial disease defined as abnormal or 
excessive fat accumulation that presents a risk to health. Obesity is 
associated with several comorbidities [1], such as cardiovascular dis-
eases (CVDs), metabolic syndrome, type 2 diabetes mellitus (T2DM), 
cancer, and according to recent studies also increased risk of severe 
COVID-19 [2]. The world-wide prevalence of obesity doubled between 
1980 and 2008 [3]. From 1980–2013 the global proportion of over-
weight individuals increased in both men (from 28.8% to 36.9%) and 
women (from 29.8% to 38%) with a trend to continued increase of the 
prevalence rate for both obesity and overweight [4]. Because of their 
increasing prevalence, significant impacts on health and medical costs, 
obesity with its comorbidities has become a public health concern. 
Traditionally, the cause of obesity is considered an imbalance be-
tween caloric intake and energy expended. It is now recognized that the 
development of obesity involves a complex interplay of biological and 
psychosocial factors [5]. Of especial relevance is that research has 
shown that a weight loss between 5% and 10% is enough to induce 
clinically relevant improvements in health risk factors such as raised 
blood glucose and other biomarkers related to augmented risk of CVD 
[6,7]. To achieve successful maintenance of weight loss over time, the 
WHO and EU [8] as well as US Academy of Nutrition and Dietetics [9] 
recommend changes in lifestyle including a diet that reduces excessive 
energy intake and improves dietary quality. However, successful treat-
ment of obesity may in several cases require adjuvant pharmacotherapy 
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[10], which is briefly reviewed in the present paper. In selected cases 
bariatric surgery can be chosen [11]. However, surgery is only recom-
mended when BMI is ≥ 40 kg/m2 or ≥ 35 mg/m2 in the presence of 
weight-related comorbidities [12]. 
Irrespective of method for obesity treatment lifestyle advice remains 
a corner-stone remedy. An individually adapted diet that succeeds in 
achieving a state of negative energy balance is recommended. Based on 
calorie calculations numerous dietary approaches can result in a 
reduction in energy intake. Frequently prescribed diets are based on 
changes in different food groups to achieve a continuous daily energy 
restriction, although intermittent energy restriction (intermittent fasting) 
has lately emerged as an alternative [13,14]. The present review aims at 
providing updated evidence regarding the most common dietary and 
pharmacological strategies to promote weight loss. Literature published 
after the year 2005 was searched in Pubmed, Medline and Google 
scholar by making use of the search keyword obesity combined with 
drugs, diets, low-fat, low-carbohydrate, fasting, weight loss or 
macronutrients. 
In the present overview currently recommended dietary approaches 
to obtain weight loss are classified into two main groups: Firstly, we 
discuss the low-fat and the low-carbohydrate concepts, as well as the 
Mediterranean dietary concept. Secondly, we discuss diets based either 
on restriction of specific food groups (“the Paleo concept”) or on inter-
mittent calorie restriction (“the intermittent fasting concept”). Included 
in our overview is also the insight that any nutritional approach is 
counteracted by physiological defense mechanisms against weight 
reduction, explaining a general acceptance of pharmacological aids to 
obtain lowering of the body weight. The “very-low-calorie diet” concept, 
defined as a diet with extremely low daily food energy intake, maximally 
800 kilocalories (3300 kJ) per day is not further discussed in the present 
overview, since this approach is only used under close medical super-
vision for up to 3 months [15] such as for rapid weight loss in morbid 
obesity before bariatric surgery. 
2. Central defense mechanisms against body weight reduction 
The recognition that there exist central mechanisms to resist changes 
in body composition, thus contributing to maintenance of the current 
body weight, represents an important insight within obesity research. 
Powerful central mechanisms triggering increased hunger and a decline 
in metabolic rate appear to operate against any dietary calorie restric-
tion. At present, we do not fully understand the molecular mechanisms 
behind this defense [16]. Experiences from bariatric surgery suggest that 
when surgical treatment leads to sustained weight loss it is because of 
changes in the defended state of obesity [17]. Therefore, understanding 
the mechanisms of body weight loss obtained by bariatric surgery is of 
importance for further development of alternative strategies. Post-
operative suppression of ghrelin levels seems to explain only a minor 
part of the postoperative weight loss [18]. Changed gut microbiota 
accompanied by changed gut-brain signaling [19], i.a. by reduced 
endocannabinoid [20] or increased butyrate synthesis [21] in the gut, 
represents other possible mechanisms [22]. Furthermore, recent 
research has disclosed that facilitated nutrient flow after surgery to the 
distal gut with its concentrated occurrence of enteroendocrine L-cells 
enhances postprandial secretion of glucagonlike peptide-1 (GLP-1) [23]. 
The recently reported observation that gastric bypass is superior to 
sleeve gastrectomy for remission of type 2 diabetes [24] conforms with 
the proposed role of increased GLP-1 secretion in the distal gut. Re-
ceptors for GLP-1 expressed in hypothalamus may explain the ability of 
this hormone to promote satiety and thereby reduce food intake [25] 
(Fig. 1). 
In the brain, a major candidate for body weight regulation is the 
middle region of hypothalamus, where appetite and perceptions of food 
are processed [26]. Here, GLP-1 stimulates secretion of melanocortins 
that act on receptors in various brain regions. Food intake and energy 
expenditure are to a large extent regulated through the melanocortin-4 
receptors, which are widely distributed within the central nervous sys-
tem, including in the hypothalamus [27]. Loss of normal melanocortin 
signaling leads to hyperphagia and obesity [28], whereas over-activity 
of the same system may lead to suppression of food intake. However, 
melanocortin-signaling appears not to be the only aspect of neural body 
weight regulation, since several cell populations in the arcuate nucleus 
operate on the same functions [29]. 
In clinical nutrition, the food palatability including smell and taste is 
considered to play an important role in appetite regulation and obesity 
pathogenesis. Diets rich in sugar and saturated fats may influence the 
regulations through their proinflammatory actions on microglia in hy-
pothalamic regions [30]. Dopamine is a crucial transmitter in the reward 
system of the brain, although appetite stimulation also depends on other 
signaling substances [31]. Recent observations have shown interactions 
between obesity and cognitive functions related to learning and memory 
[32]. Strengthening of cognitive functions may thus represent an 
appropriate strategy to modulate food intake in obese subjects [33]. A 
therapeutic challenge is to convert unhealthy habits into conscious 
behavior [34]. Accordingly, it is important to mediate adequate lifestyle 
cognition. When it comes to dietary advice (Table 1), energy restriction 
Fig. 1. Bariatric surgery is reported to lead to raised postprandial secretion of glucagon-like peptide (GLP-1) and other substances which can mediate satiety by 
signaling from gut to brain, particularly so to hypothalamic receptors. Increased activity of the hypothalamic melanocortin system may lead to suppressed food intake 
(see text). 
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is considered a sine qua non in all recommended approaches [35]. 
3. Energy restriction based on changes in macronutrient 
composition 
The energy distribution between the main three macronutrients in a 
typical Western diet, as recently determined in the mean American diet 
of adults [36] is shown in Fig. 2. Interestingly, energy from fat in peo-
ple’s diets in USA has gone down from an average of almost 40% to 
about 33% during the past 30 years, while overweight and obesity rates 
have increased substantially [37]. Of note, the Western diet of today has 
a high content of refined carbohydrates and n-6 polyunsaturated fatty 
acids (PUFA), which represent sources of proinflammatory cytokines 
and endocannabinoids that can promote weight gain [38]. The accept-
able macronutrient distribution range for adults (AMDR), as set by the 
US Food and Nutrition Board of the Institute of Medicine, advocates 
relative fat intake of 20–35%, protein intake of 10–35%, and carbohy-
drate intake of 45–65% of the total energy intake [39]. Manipulation of 
macronutrient content in otherwise energy-matched diets, even outside 
the AMDR, has been studied to determine the composition that best 
promotes weight loss. In this regard, it is known that changes in the 
macronutrient composition can affect endocrine balance and the gut 
microbiome that might impact fat storage [40]. 
3.1. Low or very-low fat intake for weight loss 
Traditionally, obesity has been considered simply the result of 
inappropriately high intake of energy-dense food, i.e., intake of a high 
proportion of fat. On this background physicians have promoted 
decreased fat intake for weight loss since the 1950s [41,42]. As ex-
pected, low-fat diets (LFDs) (Fig. 2) containing few calories can induce 
significant short-term weight loss. However, the long-term efficacy of 
such weight loss diets has proved to be rather disappointing [43], since 
the effectiveness of LFDs for weight loss in long-term studies seems not 
to differ significantly from that obtained by low-carbohydrate diets 
[44]. Here, it should be taken into account that the wide range of weight 
loss observed within each study complicates such comparisons. The 
original promotion of LFDs was based on their ability to prevent heart 
disease, next to the proclaimed effect on body weight. Lowering of fat 
intake from about 40% to about 20% of total calories was shown to 
decrease cholesterol by about 15%; which could be ascribed to reduced 
intake of saturated fat [45]. 
Whereas the regular LFD contain 20 – 25 E% as fat, the alternative 
very-low-fat variant (VLFD) contains only 10 – 20% fat [46]. To date, 
very few clinical trials have investigated the effect of VLFD on weight. A 
weight-loss study by Gardner et al. [47] did not show any significant 
differences in body fat reduction between VLFD (Ornish diet), 
low-carbohydrate (Atkins) and some other diets. However, despite the 
fact that the VLFD participants were assigned to a fat intake of about 
10%, the actual intake progressed to above 25 E% by the end of the 
12-month trial. Apparently, a targeted restriction to low or very-low fat 
intake is difficult to attain, especially in long-term studies, as the 
observed actual fat intakes typically exceed the prescribed proportions. 
When discussing LFDs or VLFDs it is of interest to note that simul-
taneous use of the lipase inhibitor orlistat could inhibit fat absorption 
significantly and also help in maintaining a low-fat intake (Table 2), thus 
leading to more pronounced weight loss compared to traditional life-
style modifications [48]. The extra weight loss obtained by orlistat 
treatment [49] may be accompanied by reduced development of T2DM 
and other risk factors for CVD [50]. 
3.2. The low carbohydrate concept 
Low carbohydrate diets (LCDs) having a low content of easily 
absorbable carbohydrates, are marketed either as high-fat (HF-LCD) or 
high-protein (HP-LCD), with the latter involving ingestion of more than 
20–25 E% from protein emerging as a particularly popular variant. 
Reasonably, the HF- and HP-variants of LCD, especially if combined with 
adequate intake of dietary fiber, will suppress secretion of ghrelin more 
efficiently than LFDs, and thus suppress the feeling of hunger. The LCD 
approach has resulted in several dietary modifications, including the 
Atkins diet (Fig. 2). 
In contrast to LCD meals, LFD-meals with high content of refined 
carbohydrates elevate postprandial glucose levels accompanied by 
increased insulin secretion, which secondarily directs fat into adipose 
tissue storage, a mechanism that has been referred to as the carbohy-
drate-insulin model of obesity [40]. In this context, low carbohydrate diets 
with low glycemic load, ranging from as low as 10% to maximally 40% 
of energy from carbohydrates, are claimed to treat obesity by reducing 
insulin secretion while simultaneously maintaining adequate 
GLP-1-levels, a hormonal shift that should lead to increased fat oxida-
tion [51]. Analogously, pharmaceuticals with GLP-1-like actions such as 
liraglutide can also increase energy expenditure [52]. 
Despite this captivating carbohydrate–insulin model of obesity, 
clinical trials comparing LCDs with low-fat diets (LFDs) in energy- 
Table 1 
Commonly recommended diets for weight loss.   
Hypothesized mechanisms 
Low fat diet (LFD) Energy restriction 
Low carbohydrate-high fat diet (LFD- 
HF) 
Energy restriction (+ induction of satiety) 
Low carbohydrate-high protein (LFD- 
HP) 
Energy restriction (+ induction of satiety) 
The Paleo diet(high in protein) Energy restriction (+ induction of 
satiety?) 
The 5:2 intermittent fasting diet Energy restriction (+ reduced appetite?)  
Fig. 2. Approximate macronutrient content, given in E%, of some popular diets 
as compared with common Western diet [35]. 
Table 2 








Liraglutide About 8% About 3% +++ [97] 
Semaglutide About 15% About 5% +++ [102] 
Orlistat About 8% About 5% ++ [104] 
Bupropion About 8% About 5% ++ [106] 
Bupropion- 
naltrexone 
About 6% About 1% ++ [111] 
Phentermine/ 
topiramate 
About 9% About 2%  [114]  
a Note: Here, the percent of weight loss is given by whole numbers, as an 
approximation, due to a wide range of weight loss within each study. 
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equivalent modifications have reported similar weight loss [53,54]. In 
accordance with this, a compilation of relevant studies done by an 
expert panel in 2013 concluded that consumption of a 
carbohydrate-restricted diet resulted in equivalent weight loss as a 
low-fat diet with comparable calorie restriction [55]. Recently, this 
conclusion was confirmed in a randomized clinical trial of 609 over-
weight and obese adults following a healthy low-fat diet or a healthy 
low-carbohydrate diet for 12 months showing no significant difference 
in weight loss [56]. A recent meta-analysis of diets where the protein 
intake was controlled found only a marginal benefit of keeping a low-fat 
rather than a low-carbohydrate diet, the difference being considered 
without clinical significance [57]. 
However, the carbohydrate-insulin model of obesity may apply to 
selected cases of pathological hyperinsulinemia. It is still recommended 
to treat obese individuals with T2DM and/or insulin resistance with 
appropriate kinds of LCDs [58], which in some cases is combined with a 
GLP-1 agonist. Thus, nutritional treatment of obesity should take into 
account whether the patient is insulin resistant or has a normal insulin 
response. 
An extreme variant of LCD–HF diet, known as the ketogenic diet 
(KD), prescribes intake of at least 70% of energy from fat and a severe 
restriction of carbohydrates (maximally 10 E%) to mimic a fasting state 
and induce ketosis [59]. KD has been used to promote a rapid weight loss 
and it may also reduce appetite [60]. Clinical trials have reported sig-
nificant weight reduction for individuals on this diet [61,62]. However, 
adverse effects of KD should be taken into account, which include 
headaches, muscle cramps, and general weakness [63], and some studies 
have demonstrated worsening of the lipid profile [64]. 
High and very high-protein diets (HP diets), in which >20–35% of 
energy is derived from protein appear to offer advantages for short-term 
weight loss [65]. In accordance with this, popular HP diets such as the 
Atkins variant, promotes significant weight loss over a short time span 
[66]. Upon very high intake, proteins appear to act on relevant meta-
bolic targets, increasing satiety and also total energy expenditure [67, 
68]. Proteins are thus more efficient than carbohydrates at inducing 
thermogenesis [69]. An important mechanism behind this appears to be 
activation of brown and beige adipocytes with increased uncoupled 
respiration including futile cycling with loss of ATP [70]. Also, the 
source of proteins appears to be important for its impact on dietary 
induced thermogenesis, with vegetarian sources seeming to be the most 
effective. Increased protein turnover including its promotion of 
increased synthesis of urea are energy-requiring metabolic processes 
[71]. 
Regarding long-term use, exceeding 6–12 months, it should be taken 
into account that the clinical benefits HP-diets compared with LF-diets 
seems to be small, and if combined with high intake of saturated fat 
HP-diets may cause undesired effects by increasing LDL cholesterol and 
CVD risk [72]. 
Altogether, in a short-term perspective, HP-LCDs, as well as keto-
genic diets, are suggested to be beneficial for weight-loss. However, 
owing to their major effects on metabolic processes, their utilization 
should be restricted to the initial phase of a weight loss regimen, lasting 
for up to 6–12 months, and not be recommended as diets for life [73]. 
However, when using a LCD composition with high intakes of dietary 
fibers, a protein-rich variant may be preferred for weight management 
also after an initial weight-loss period [74]. 
3.3. The Mediterranean diet for weight-loss 
After an initial period on a high-protein-LCD or an orlistat-LFD diet, 
the Mediterranean diet [75] may represent an attractive option for 
continued dieting, provided that it is prescribed in an energy-restricted 
form. Mediterranean diet is not a typical low carbohydrate diet (Fig. 2). 
It is rich in plant-based foods, having high levels of antioxidants and 
dietary fiber, and low glycemic load compared to conventional Western 
diets. The Mediterranean diet is characterized by high intake of 
vegetables, fruits, whole-grain cereals, seafood, olive oil, and nuts. In 
contrast to conventional Western diets, this diet contains more adequate 
composition of fatty acids, as it contains less saturated fat and n-6 PUFA, 
and more MUFA and n-3 PUFA. 
Successful weight loss with the Mediterranean diet has been re-
ported, not only in the short term [76], but also in the long term [77], 
with weight losses being comparable to those obtained with other diets 
in overweight individuals, provided that comparable caloric restrictions 
are prescribed [78]. 
Of importance, the Mediterranean diet has been related to a variety 
of health benefits in addition to its effect on body weight. It has been 
shown that Mediterranean diet with its low glycemic load improves 
glycemic control in patients with T2DM [79], and it has also been 
associated with a reduction of inflammatory biomarkers, and reduction 
of other markers for CVD risk [80]. 
4. Concepts based on the restriction of specific foods or on 
intermittent fasting 
Different foods and food groups have been categorized as harmful by 
some popular nutritionists and have been removed from specific diets, 
allegedly to promote weight loss. Among these specific diets are vege-
tarian diet, which excludes all animal products, and also the Paleo diet, 
which excludes several food groups including grains and dairy products. 
It should be noted, however, that vegetarian diets are not specifically 
designed for weight loss. Some people decide to go for this lifestyle 
simply because they cannot not bear the thought of harming living 
creatures. Others have converted to this diet for religious reasons, or for 
its benefits for worldwide food sustainability. A vegetarian plan can 
range from the simple exclusion of meat products to a vegan plan that 
includes only raw vegetables, fruits, nuts, seeds, legumes, and whole 
grains [81]. Notably, plant-based diets vary greatly in composition and 
possible health effects. While plant-based diets containing high amounts 
of healthy foods such as fruits, vegetables, nuts, and legumes are asso-
ciated with lowered risk for CVD, plant-based diets including high 
amounts of refined foods and beverages rich in sugar, are associated 
with increased risk of CVD [82]. 
4.1. Paleolithic diet and weight-loss 
The Paleo diet is based on adoption of food intakes that mimic the 
food groups of our pre-agricultural hunting and gathering ancestors 
[83]. This diet is proclaimed to optimize health, and also to result in 
weight loss. These statements are supported by the knowledge that a 
hunter–gatherer lifestyle has characterized humanity and its ancestors 
for hundred-thousands of years, causing the human genome to be 
adapted to it. According to advocates of the Paleo diet, the human 
genome has not been adapted to the radical lifestyle changes accom-
panying modern civilization [84]. 
Only foods that were available in the hunting-gathering stage of the 
development of mankind can be included in this diet, such as meat, nuts, 
eggs, fruits, berries and vegetables, whereas sugar, cereals, dairy prod-
ucts, and other refined products are excluded. Characteristics of the 
Paleo diet include a low ratio of n-6 to n-3 fatty acids along with a high 
content of phytochemicals that might promote health benefits. The diet 
is high in protein (25–35% of energy) and moderate in fat and carbo-
hydrates including low in glycemic ones [85]. Possible benefits of the 
Paleo diet include ameliorations in insulin resistance and T2DM, 
reduction of CVD risk factors [86] and also beneficial modulation of 
intestinal microbiota [87]. Reductions of body weight and body fat mass 
in those who follow Paleo diet have been reported, both from short- and 
long-term studies [88,89]. However, concerns have been raised 
regarding problems with long-term adherence and high costs of this diet. 
Taken together, available evidence suggests health benefits of Paleo 
diet, although it has not proven more efficient than more conventional 
diets for weight loss. The hypothesis of the Paleo advocates regarding 
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the immutability of the Paleolithic human genome is not necessarily 
correct. 
4.2. Weight reduction diets based on intermittent energy restriction 
Traditional guidelines for weight reduction recommend continuous 
energy restriction along with lifestyle intervention. However, more 
recently, intermittent energy restriction involving restricted energy 
intake allocated to certain periods of the day or to certain days during 
the week, has received considerable attention as an alternative strategy. 
The term intermittent fasting (IF) refers to regular periods with very low 
or no caloric intake. The IF approach may include various modifications, 
such as a 24-hour fasting on alternate days, or fasting for two non- 
consecutive days per week, the latter modification being referred to as 
the 5:2 diet [14]. The aim of modern IF is to reduce the average caloric 
intake over time. In addition, IF appears to promote remodeling of the 
gut microbiome with upregulation of intestinal butyrate production 
[90], which might contribute to the observed improved insulin sensi-
tivity and reduction of inflammatory biomarkers [91,92]. Most of the 
human studies on IF have been limited to short term interventions, and 
the results are somewhat inconsistent. An updated meta-analysis of RCT 
trials summarizing recent evidence has concluded that intermittent en-
ergy restriction is comparable with continuous energy restriction for 
promoting weight loss [93]. Although appropriate control groups are 
lacking in some studies, it has been suggested that the beneficial effects 
of IF are comparable to those of other types of caloric restriction [13]. 
However, the long-term adherence of IF is unclear. In some cases, 
adequate compliance with the fasting intervals may turn out to require 
pharmacological support (Table 2). 
5. Pharmacological aids 
Commonly used drugs for weight reduction are listed in Table 2. If 
for some reason lifestyle measures have not led to an acceptable result 
after about 12 months, adjuvant drug treatment may be considered. 
According to current guidelines, drugs approved for weight manage-
ment should then be considered for patients with a BMI of ≥30 kg/m2 or 
a BMI ≥27 kg/m2 in the presence of weight-related comorbidities [12]. 
The initial choices in such cases may be the GLP-1 agonist liraglutide or 
the lipase inhibitor orlistat. The bupropion/naltrexone combination 
might be preferred in selected cases. Regarding phentermine and its 
combination with topiramate, which are approved in USA, these agents 
have not been approved in Europe and are only briefly discussed here. 
5.1. Liraglutide and semaglutide 
Liraglutide is a GLP-1 agonist initially approved in 2010 for treat-
ment of T2DM at doses of 1.8 mg s.c. daily. Early observations indicated 
that liraglutide could also decrease appetite and enhance satiety, pre-
sumably through effects on the central nervous system [94]. Early 
experimental studies indicated that liraglutide exerted its impact on the 
arcuate nucleus in hypothalamus [95], mimicking the effects of natural 
GLP-1. These findings led to the development of liraglutide for treatment 
of obesity. A 20-week trial in patients with obesity demonstrated that 
liraglutide treatment led to a dose-dependent weight loss of up to 4.4 kg, 
compared with 3.0 kg, for placebo [96]. One of the subsequent phase-3 
trials, randomized overweight/obese patients to receive daily liraglutide 
(3.0 mg s.c.) or placebo for one year [97]. The weight loss in the lir-
aglutide group was in average 8.0% compared with 2.6% in the 
placebo-treated group. Also in patients with prediabetes, the liraglutide 
treatment was associated with greater weight loss than placebo, with an 
estimated treatment difference of – 4.3% as monitored after 3 years 
[98]. Furthermore, the time-to-onset of T2DM in prediabetic patients 
was substantially prolonged with liraglutide. In order to compare weight 
maintenance in overweight patients without diabetes after an average of 
6% weight loss with energy-restricted dieting, the studied subjects were 
randomized either to liraglutide (3.0 mg daily) or to placebo [99]. 
During this maintenance period, the weight loss with liraglutide was 
6.2% and with placebo 0.2%. Nausea, vomiting, and diarrhea may occur 
as side effects of liraglutide. A drawback with this drug is that it has to be 
given by daily subcutaneous injections. A recently developed drug with 
similar effect profile, semaglutide, can be administered by weekly in-
jections [100]. A recent 68-week placebo-controlled trial in patients 
with obesity found that semaglutide treatment (2.8 mg weekly) led to a 
weight loss of 14.9% compared with 2.4% with placebo [101], while 
another study with similar design and follow-up period found a 
weight-loss of 16% with semaglutide and 5.7% with placebo [102]. Oral 
administration of semaglutide is under investigation [103]. The latter 
drug has yet not been approved for clinical use against obesity, but is 
used in the treatment of T2DM. 
5.2. Orlistat 
Orlistat is a pancreatic lipase inhibitor that reduces intestinal ab-
sorption of fat by about one-third. At doses of 120 mg x 3 p.o. for 12 
months, it results in a weight loss of about 8% compared with about 5% 
with placebo [104]. Low-dose orlistat (60 mg x 3) which is approved for 
use without prescription results in a somewhat less weight loss. The 
mechanisms of action of orlistat may involve not only reduced fat ab-
sorption, but secondarily also raised postprandial secretion of GLP-1, 
thus mediating satiety by gut-to-brain signaling. As such, orlistat facil-
itates the flow of non-absorbed fat to the distal gut, with its rich 
occurrence of GLP-1-producing enteroendocrine L-cells. Orlistat has 
been approved for weight management of obese adolescents of age 12 
years and above. Adverse effects of orlistat are diarrhea, frequent 
defecation and fecal incontinence. Supplements with fat-soluble vita-
mins, in particular with vitamin D3, are recommended to subjects on 
LFDs when used in combination with orlistat treatment [105]. 
5.3. Bupropion and the bupropion-naltrexone combination 
Bupropion is a norepinephrine and dopamine reuptake inhibitor that 
is used for treatment of depression [106]. It activates 
pro-opiomelanocortin (POMC), a neuropeptide that appears to decrease 
appetite by affecting hypothalamic functions. It is probably the 
alpha-melanocyte-stimulating hormone produced by enzymatic 
cleaving of POMC that has the effects on food intake, presumably by 
acting on the melanocortin-4 receptor. Bupropion has been shown to 
promote clinically significant weight loss in obese individuals [107]. 
Upon combination with the opioid antagonist naltrexone, it has been 
shown to alleviate addictive over-eating [108]. Naltrexone monotherapy 
has been used for the treatment of opioid- and alcohol-dependence. 
Naltrexone inhibits the appetite-enhancing effects of beta-endorphin 
caused by cannabinoid-1 receptor activation, and it has been observed 
to decrease food cravings in obese and binge-eating humans [109]. The 
combined use of bupropion and naltrexone has a synergistic effect on 
appetite suppression [110]. This may be because the addition of 
naltrexone can enhance the bupropion-induced POMC activation and 
thus strengthen its appetite-suppressing effects. 
Combination of bupropion with a low dose of naltrexone resulted in 
more pronounced weight loss compared to bupropion monotherapy in a 
24-week trial [110]. In a phase-3 study, bupropion (360 mg/day) 
combined with naltrexone (32 mg/day) resulted in a weight loss of 
about 6%, compared with about 1% for placebo [111]. Some concern 
was expressed because this treatment was associated with a mean in-
crease in systolic and diastolic blood pressure of about 3 mmHg, relative 
to a placebo. However, in a follow-up study there was no difference in 
major cardiovascular events between patients given active treatment vs. 
those on placebo [112], though the study was performed within a rather 
short time frame, precluding analyses of long-term effects. Adverse ef-
fects of the naltrexone/bupropion combination include constipation and 
dry mouths in addition to headache, insomnia, and anxiety. 
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5.4. Phentermine and phentermine-topiramate combination 
Phentermine is an amphetamine analogue. It is approved for medical 
use in USA, though restricted to short-term use for up to 12 weeks. It is 
not approved in Europe due to its pharmacological similarities with 
amphetamine. A meta-analysis has estimated that treatment with 
phentermine (30 mg/day) for about 3 months results in a mean weight 
loss of about 3 kg relative to a placebo [113]. Among the side effects of 
phentermine are dry mouth and constipation, in addition to agitation 
and insomnia in some cases. 
The combination of low-dosed phentermine with low-dosed top-
iramate has been investigated for treatment of obesity, with most of the 
studies being done in USA. Monotherapy with topiramate was initially 
reported to lead to significant weight loss [114], but the risk associated 
with its use in efficient doses, including severe psychiatric adverse ef-
fects, did not allow further development of this monotherapy for clinical 
use. However, when combining low-dosed topiramate (100 mg/day) 
with a low dose of phentermine (15 mg/day) it was observed that a 
6-month treatment led to reduced energy intake and a substantial 
weight loss compared to placebo [115]. However, also this combination 
gave rise to frequently occurring adverse effects such as paresthesia, and 
less frequently cognitive dysfunction and psychiatric events, explaining 
the refusal by European Medicines Agency as regards marketing 
authorization in the EU countries. 
6. Diet-drug combinations 
For any dietary regimen, research has indicated that a high level of 
adherence is crucial for successful achievement of weight loss [116, 
117]. To obtain desired degrees of adherence and weight loss, the 
importance of integrating dietary modifications into a regimen of 
adapted physical activity has been emphasized [118]. In some subjects, 
pharmacotherapy is also indicated. Diet-drug combinations should be 
considered a valuable tool for patients who have not experienced 
adequate benefit from lifestyle interventions during a 12-month period 
or who have difficulties in adhering to dietary protocols [119]. Although 
we do not have substantial information about diet-drug combinations 
from available research, there are known factors clinicians should 
consider, based on the actions of the various drugs. Thus, for patients 
who report intense food cravings, naltrexone/bupropion may represent 
a beneficial option [120], which is also true for patients who struggle 
with addiction or reduced impulse control. Moreover, the drug liraglu-
tide combined with LCD (low carbohydrate diet) appears to be recom-
mendable for weight loss in obese patients with prediabetes or T2DM 
[121], an approach that can be combined with metformin which has 
been claimed to act as a GLP-1 enhancer [122]. A diet rich in dietary 
fibers [123], e.g. a plant-based food with high levels of antioxidants and 
essential trace element may be appropriate for patients with BMI 
> 25 kg/m2 and fluctuating blood glucose values. Here, it should be 
noted that in Western populations the average intake of dietary fiber 
(about 15 g/day) [124] is less than half of the health-based recom-
mended levels (28–36 g/day), and it is even lower in subjects with 
T2DM or high blood pressure [125]. Finally, the lipase inhibitor orlistat 
in combination with dietary modifications appears to be the drug of 
choice for obese individuals who need to reduce their fat intake, i.a. as a 
therapeutic measure for the management of hypercholesterolemia 
[126]. 
7. Conclusion 
To conclude, it should be admitted that the current evidence for 
recommending specific diets and diet-drug combinations for weight loss 
remains weak, which in part can be attributed to differences in dietary 
protocols and different follow-up times in available trials. In the initial 
phase of a dietary intervention several diets promote obvious degrees of 
success, such as for instance the LFD-orlistat combination or the high 
protein-LCD combination. However, in the longer term, there are only 
minimal differences between various approaches, precluding prescrip-
tion of one diet over another to anyone. 
Present knowledge indicates that obese individuals with T2DM or 
metabolic syndrome can profit from using the LCD/low glycemic- 
liraglutide drug-diet combination, whereas some non-diabetics might 
profit from the LFD-orlistat combination, with the drugs typically being 
prescribed after an initial period of lifestyle modifications. At present, it 
is not possible to conclude that there is an optimal long-term diet-drug 
combination for procuring weight loss or weight maintenance for 
anyone. Furthermore, due to the possible adverse effects of the pre-
scribed drugs, caution is warranted. For example, when using pharma-
cological agents such as the bupropion-naltrexone combination to 
increase adherence to a calorie-restricted diet, the risk of side effects is 
significant, requiring adequate medical surveillance. The future might 
also bring new therapeutic agents that might help in medical treatment 
of obesity and its complications. At present, inhibitors of the sodium- 
glucose transporter 2 are under investigation for clinical use in obesity 
treatment. Regardless of the chosen therapeutic approach, a funda-
mental point for weight loss is to adopt a diet that creates a permanently 
negative and acceptable energy balance. At the same time diets pre-
scribing high-quality and health-promoting foods should be encouraged. 
Among questions for further research are: How do different diets change 
hormonal secretion, gut microbiome composition, and gene expression? 
How do these changes influence hunger, satiety and appetite, and en-
ergy expenditure? 
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